Altogether, these results demonstrated that melanoma tumor cells specifically alter CLR expression profiles of healthy DC subsets, both directly and indirectly through soluble factors depending on the DC subset, suggesting that melanoma tumor cells displayed and released glycans or DAMPs that may interact with DCs through CLR molecules. This evidence concerns the gene DCLK3 and neoplasm.